The invention relates to the use of omega-3 fatty acid(s) or the marine and/or vegetable omega-3 fatty acid(s) source for preparing a drug for treating a hypercholesterolemia caused by the anti-retroviral treatment of patients infected by human immunodeficiency virus (HIV) by limiting a non-HDL fraction of circulating lipoproteins and to a combined product comprising at least one type of omega-3 fatty acid and at least one type of anti-retroviral agent for simultaneous, separate or temporally gradual use.